Arrowhead To Receive Up To $2 Billion As Part of Novartis Pact For siRNA ARO-SNCA

Recently, Arrowhead Pharmaceuticals announced that it was able to establish a deal with big pharma Novartis relating to the development

Cytokinetic’s Aficamten Push Bests SOC In Heart Muscle Disorder

Serina Establishes Registrational Study For SER-252 In PD Under Specific FDA Pathway

Viking’s Stock Craters After Mid-Stage Obesity Trial Data With Oral Drug VK7235

Precigen Scores FDA Approval Of Immunotherapeutic PAPZIMEOS For Rare Respiratory Disease

Latest news

Arrowhead To Receive Up To $2 Billion As Part of Novartis Pact For siRNA ARO-SNCA

Cytokinetic’s Aficamten Push Bests SOC In Heart Muscle Disorder

Serina Establishes Registrational Study For SER-252 In PD Under Specific FDA Pathway

Viking’s Stock Craters After Mid-Stage Obesity Trial Data With Oral Drug VK7235

Top editors picks!

  • Featured, Top 3
  • Latest news, Other articles, Top editors picks!

Viking’s Stock Craters After Mid-Stage Obesity Trial Data With Oral Drug VK7235

1

  • Featured, Top 1
  • Latest news, Other articles, Top editors picks!

Precigen Scores FDA Approval Of Immunotherapeutic PAPZIMEOS For Rare Respiratory Disease

2

  • Featured, Top 1
  • Latest news, Other articles, Top editors picks!

Novartis’ Win Streak With Ianalumab Continues With Solid ITP Treatment Data Release

3

  • Featured
  • Latest news, Other articles, Top editors picks!

Bicycle Reduces 25% Of Staff Amid Second Half Of 2025 Program Updates Expected

4

Other articles

Arrowhead To Receive Up To $2 Billion As Part of Novartis Pact For siRNA ARO-SNCA

Cytokinetic’s Aficamten Push Bests SOC In Heart Muscle Disorder

Serina Establishes Registrational Study For SER-252 In PD Under Specific FDA Pathway

Viking’s Stock Craters After Mid-Stage Obesity Trial Data With Oral Drug VK7235

Precigen Scores FDA Approval Of Immunotherapeutic PAPZIMEOS For Rare Respiratory Disease

One Patient Death Due To Kidney Injury In CytomX’s Ongoing Development Of CX-2051

ORIC Reduces Workforce by 20% But Set To Tackle Two Late-Stage Programs In 2026

Novartis’ Win Streak With Ianalumab Continues With Solid ITP Treatment Data Release

Novartis Scores Huge Win In Sjögren’s disease With Dual Action Monoclonal Antibody Ianalumab

Join Newsletter Today!

Enter your email and get information about the newest posts.
Scroll to Top